[
  {
    "ts": null,
    "headline": "What TrumpRx Means For Controversial Plan To Lower U.S. Drug Prices",
    "summary": "The White House unveiled TrumpRX as a key part of the administration's plan to lower U.S. drug prices. But serious questions remain.",
    "url": "https://finnhub.io/api/news?id=93ac76ddd429a06740265adee35ea6d9b3e54d0928f18a545bba2f355d2568ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759269170,
      "headline": "What TrumpRx Means For Controversial Plan To Lower U.S. Drug Prices",
      "id": 136943997,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The White House unveiled TrumpRX as a key part of the administration's plan to lower U.S. drug prices. But serious questions remain.",
      "url": "https://finnhub.io/api/news?id=93ac76ddd429a06740265adee35ea6d9b3e54d0928f18a545bba2f355d2568ed"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know",
    "summary": "Bristol Myers Squibb (BMY) reached $45.1 at the closing of the latest trading day, reflecting a +2.15% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=77816ec49e00e0d76f6a8a9fa2c54ca72cd3cff96d230b77319e8b129036c33d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759268704,
      "headline": "Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know",
      "id": 136944379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb (BMY) reached $45.1 at the closing of the latest trading day, reflecting a +2.15% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=77816ec49e00e0d76f6a8a9fa2c54ca72cd3cff96d230b77319e8b129036c33d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Soars on Trump’s New Drug Pricing Plan. Here’s Why.",
    "summary": "The president announced a federal government website that allows Pfizer to sell medicines at low prices to cash-paying consumers.",
    "url": "https://finnhub.io/api/news?id=04fbe0d5e9ce27db4ee3192e9532cb87df0019d8869b7be49ff119c8cd315884",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759265220,
      "headline": "Pfizer Stock Soars on Trump’s New Drug Pricing Plan. Here’s Why.",
      "id": 136944001,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The president announced a federal government website that allows Pfizer to sell medicines at low prices to cash-paying consumers.",
      "url": "https://finnhub.io/api/news?id=04fbe0d5e9ce27db4ee3192e9532cb87df0019d8869b7be49ff119c8cd315884"
    }
  },
  {
    "ts": null,
    "headline": "Bernstein Maintains a Hold on Bristol-Myers Squibb Company (BMY)",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best large cap value stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) without assigning a price target. Bristol-Myers Squibb Company (NYSE:BMY) reported $12.3 billion in revenues in fiscal Q2 2025, with […]",
    "url": "https://finnhub.io/api/news?id=393d3cea183c060c09f5cd79a6237c69efff3ca6269171386567c35d75ecd6ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759258174,
      "headline": "Bernstein Maintains a Hold on Bristol-Myers Squibb Company (BMY)",
      "id": 136944381,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best large cap value stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) without assigning a price target. Bristol-Myers Squibb Company (NYSE:BMY) reported $12.3 billion in revenues in fiscal Q2 2025, with […]",
      "url": "https://finnhub.io/api/news?id=393d3cea183c060c09f5cd79a6237c69efff3ca6269171386567c35d75ecd6ce"
    }
  },
  {
    "ts": null,
    "headline": "Trump's Plan To Lower U.S. Drug Prices Faces Big Test",
    "summary": "But Trump might get less than he bargained for as drugmakers focus on prices abroad, rather than stateside efforts.",
    "url": "https://finnhub.io/api/news?id=456cd7f18059a60e00155564da4afeaff3d33c28c548a0a16c1e0af0e445e3eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759250909,
      "headline": "Trump's Plan To Lower U.S. Drug Prices Faces Big Test",
      "id": 136937584,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "But Trump might get less than he bargained for as drugmakers focus on prices abroad, rather than stateside efforts.",
      "url": "https://finnhub.io/api/news?id=456cd7f18059a60e00155564da4afeaff3d33c28c548a0a16c1e0af0e445e3eb"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Rises After WSJ Reports Company Will Cut Drug Costs",
    "summary": "Pfizer shares rose 2.8% Wednesday midday after The Wall Street Journal reported the pharmaceutical company would unveil a plan, alongside the Trump administration, to cut drug costs later Tuesday. Here's what to know:    The White House also plans to unveil a direct-to-consumer website for Americans to buy medication.",
    "url": "https://finnhub.io/api/news?id=6a633f4e3f072a0287e080921366b4652de528670a7645f164a019cf9fd539e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759247240,
      "headline": "Pfizer Stock Rises After WSJ Reports Company Will Cut Drug Costs",
      "id": 136937619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pfizer shares rose 2.8% Wednesday midday after The Wall Street Journal reported the pharmaceutical company would unveil a plan, alongside the Trump administration, to cut drug costs later Tuesday. Here's what to know:    The White House also plans to unveil a direct-to-consumer website for Americans to buy medication.",
      "url": "https://finnhub.io/api/news?id=6a633f4e3f072a0287e080921366b4652de528670a7645f164a019cf9fd539e4"
    }
  },
  {
    "ts": null,
    "headline": "Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?",
    "summary": "KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.",
    "url": "https://finnhub.io/api/news?id=5284b305c668b24cc9631e0ed846cb7a60ee4773224679e3226638e0f1dee45e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759241880,
      "headline": "Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?",
      "id": 136937686,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.",
      "url": "https://finnhub.io/api/news?id=5284b305c668b24cc9631e0ed846cb7a60ee4773224679e3226638e0f1dee45e"
    }
  },
  {
    "ts": null,
    "headline": "7 Ideal \"Safer\" Dividend Buys From 61 September Graham Value All-Stars (GVAS)",
    "summary": "7 Ideal \"Safer\" Dividend Buys From 61 September Graham Value All-Stars (GVAS)",
    "url": "https://finnhub.io/api/news?id=7541357ddeb121bc1bfda61240900c5c56a2a915721b71f97a1ef21e576562a1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759234564,
      "headline": "7 Ideal \"Safer\" Dividend Buys From 61 September Graham Value All-Stars (GVAS)",
      "id": 136937269,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7541357ddeb121bc1bfda61240900c5c56a2a915721b71f97a1ef21e576562a1"
    }
  },
  {
    "ts": null,
    "headline": "Genmab Strikes $8 Billion Deal for Cancer Treatment Maker Merus",
    "summary": "BMO analysts said in a note Monday they were “encouraged” that Genmab’s acquisition “could start to spur broader M&A in the sector.”",
    "url": "https://finnhub.io/api/news?id=5e6093f3a5511a13b171e615c5fa9bdd4a507ce70ae291aa8eda81457ffd1f08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759228200,
      "headline": "Genmab Strikes $8 Billion Deal for Cancer Treatment Maker Merus",
      "id": 136937616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMO analysts said in a note Monday they were “encouraged” that Genmab’s acquisition “could start to spur broader M&A in the sector.”",
      "url": "https://finnhub.io/api/news?id=5e6093f3a5511a13b171e615c5fa9bdd4a507ce70ae291aa8eda81457ffd1f08"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) to Capitalize on Cell Therapy Edge to Pursue CAR-T Treatment Opportunities",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best conservative stocks to buy now. On September 23, at the Bernstein Insights: Healthcare Leaders and Disruptors, the company emphasized its leadership in cell therapy. The remarks come on the company treating 13,000 patients with cell therapy while leveraging extensive clinical data. Likewise, it is currently working […]",
    "url": "https://finnhub.io/api/news?id=650541d3402b1f8cd0004553a6acb74c17cb355c38b100298bdba097fae747c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759219244,
      "headline": "Bristol-Myers Squibb Company (BMY) to Capitalize on Cell Therapy Edge to Pursue CAR-T Treatment Opportunities",
      "id": 136934263,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best conservative stocks to buy now. On September 23, at the Bernstein Insights: Healthcare Leaders and Disruptors, the company emphasized its leadership in cell therapy. The remarks come on the company treating 13,000 patients with cell therapy while leveraging extensive clinical data. Likewise, it is currently working […]",
      "url": "https://finnhub.io/api/news?id=650541d3402b1f8cd0004553a6acb74c17cb355c38b100298bdba097fae747c1"
    }
  },
  {
    "ts": null,
    "headline": "Trump visa curbs push U.S. firms to consider shifting more work to India",
    "summary": "BENGALURU/HYDERABAD (Reuters) -Donald Trump's H-1B visa crackdown will hasten U.S. firms' shift of critical work to India, turbocharging the growth of global capability centres (GCCs) that handle operations from finance to research and development, economists and industry insiders say.  The world's fifth-largest economy is home to 1,700 GCCs, or more than half the global tally, having outgrown its tech support origins to become a hub of high-value innovation in areas from design of luxury car dashboards to drug discovery.  Trends such as growing adoption of artificial intelligence and increasing curbs on visas are pushing U.S. firms to redraw labour strategies, with GCCs in India emerging as resilient hubs blending global skills with strong domestic leadership.",
    "url": "https://finnhub.io/api/news?id=16e0446d5d9a82f5377eec1c4709f89aec15bdfa3cd11ba1677ede532e5b1794",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759212075,
      "headline": "Trump visa curbs push U.S. firms to consider shifting more work to India",
      "id": 136934204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BENGALURU/HYDERABAD (Reuters) -Donald Trump's H-1B visa crackdown will hasten U.S. firms' shift of critical work to India, turbocharging the growth of global capability centres (GCCs) that handle operations from finance to research and development, economists and industry insiders say.  The world's fifth-largest economy is home to 1,700 GCCs, or more than half the global tally, having outgrown its tech support origins to become a hub of high-value innovation in areas from design of luxury car dashboards to drug discovery.  Trends such as growing adoption of artificial intelligence and increasing curbs on visas are pushing U.S. firms to redraw labour strategies, with GCCs in India emerging as resilient hubs blending global skills with strong domestic leadership.",
      "url": "https://finnhub.io/api/news?id=16e0446d5d9a82f5377eec1c4709f89aec15bdfa3cd11ba1677ede532e5b1794"
    }
  }
]